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Background: Data on the effects of long-term treatment with azithromycin (AZM) on inflamma-
tory markers in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa are
scarce. So far there is no pharmacokinetic and clinical data on once-weekly dosage of AZM in
CF patients.
Methods: In a randomised double-blind, placebo-controlled trial, patients received AZM or pla-
cebo 1 per week for 8 weeks (AZM dosage e 20e29 kg: 500 mg, 30e39 kg: 750 mg, 40e49 kg:
1000 mg and 50 kg: 1250 mg) after a course of intravenous antipseudomonal antibiotics. Pul-
monary function tests, the serum markers LPS-binding protein (LBP), interleukin-8 (IL-8), CRP,
P. aeruginosa alginate in sputum samples and quality of life scores were evaluated.
Results: Thirty-eight patients (21 AZM/17 placebo) (mean age: 23.7 years; mean FEV1: 62% of
predicted) were recruited. After treatment (mean dose of 21.2 mg/kg body weight once
a week) pulmonary function declined in both groups compared to baseline (i.e. after cessation
of IV antibiotics). The AZM group was significantly better for mean changes in serum CRP (AZM:
þ0.9 mg/l, placebo: þ21.6 mg/l, pZ 0.019), lipopolysaccharide binding protein in serum, LBP
(AZM: þ0.9 mg/ml, placebo: þ7.0 mg/ml, pZ 0.015), serum interleukin-8 (AZM: 3.1 pg/ml,
placebo: þ2.9 pg/ml, pZ 0.001) and alginate in sputum (AZM: þ85 mg/ml, placebo:
þ353 mg/ml, pZ 0.048). Quality of life was significantly better after AZM and there was no
increase in treatment-related adverse events.8 28733333; fax: þ49 228 28733343.
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1644 G. Steinkamp et al.Conclusion: Once-weekly azithromycin ameliorated inflammatory reactions and improved
quality of life. A decline of pulmonary function after cessation of IV antibiotics could not be
prevented.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic infection with mucoid variants of Pseudomonas aer-
uginosa affects approximately 80% of adult patients with
cystic fibrosis.1 These pathogens produce alginate, a mucoid
exopolysaccharide, which is a major component of bio-
films.2 By growing in microcolonies and biofilms, these
pathogens resist both the host’s innate immune mechanism
and antibiotic treatments. Thus, even after a clinically suc-
cessful 2-week course of intravenous antipseudomonal anti-
biotics, P. aeruginosa can be identified in respiratory
secretions of the majority of patients, though in decreased
numbers and density compared to baseline.
Chronic bacterial infection leads to progressive destruc-
tion of airway tissue, respiratory failure, and finally to
premature death. Part of the problem is an inflammatory
reaction dominated by neutrophils, which are recruited
into the bronchial airways where they produce and release
proteases and oxidants. Bronchial lavage studies have
shown evidence of inflammation even in patients with
‘‘normal’’ lung function.3,4 Although regular antibiotic
treatment with inhaled, oral or intravenous antibiotics, is
able to decrease the bacterial load, there is a desire for
an effective immunomodulatory drug which could amelio-
rate the exaggerated immune response.
Macrolides do not seem to have relevant antimicrobial
effects against Pseudomonas strains, at least under usual
laboratory conditions.5 However, azithromycin and other
macrolide drugs possess important anti-inflammatory activ-
ities. They appear to suppress the interleukins (IL)-1b, IL-6,
IL-8, and tumour necrosis factor-alpha (TNF-a), inhibit neu-
trophil chemotaxis, and reduce the concentrations of neu-
trophil elastase. Furthermore, macrolides were able to
disrupt the integrity of the P. aeruginosa biofilms and to
interfere with quorum-sensing-dependent virulence factor
production in vitro.6,7
Diffuse panbronchiolitis is a lung disease that shares with
CF the chronic mucoid P. aeruginosa infection. After macro-
lides had proven to be effective in Japanese patients, phy-
sicians in the United Kingdom (UK) used azithromycin in
selected patients with cystic fibrosis. A pilot study in chil-
dren and adolescents showed relevant improvements in
lung function.8 These promising results led to the conduct
of several prospective, randomised, double-blind trials
comparing azithromycin with placebo.9e11 In these studies,
azithromycin improved lung function, prolonged the exac-
erbation-free interval, and was well tolerated. Interest-
ingly, it was recently shown that long-term use of
azithromycin in young patients with cystic fibrosis has a ben-
eficial effect on lung disease expression even before
chronic P. aeruginosa colonization is present.12 A Cochrane
report concluded that there is clear evidence of a small but
significant improvement in respiratory function following
treatment with azithromycin.13 As a consequence, manyCF centres have prescribed azithromycin as long-term
treatment for lung disease in CF.14
To elucidate further the clinical and immunomodulatory
effects of azithromycin, we planned a trial in patients who
had successfully completed a course of intravenous
antipseudomonal antibiotics immediately before study
medication was commenced. We hypothesized that azi-
thromycin would diminish the decline in lung function
usually observed after cessation of intravenous treatment,
and that the macrolide would ameliorate inflammatory
reactions compared to placebo. In the previous trials,
azithromycin had been administered in doses of (in adults)
either 250 or 500 mg per day, or 500 mg administered on
Mondays, Wednesdays, and Fridays. This translates into
weekly doses of between 1500 and 3500 mg. Considering
the pharmacokinetics of azithromycin with effective serum
concentrations even after 10 days of administration,15 we
administered the drug only once per week in a dose of
1250 mg (for patients >50 kg). Here we report the clinical
and immunomodulatory efficacy, tolerability and impact
on quality of life after 8 weeks of treatment with the new
therapeutic regimen.Methods and materials
Study design and eligibility criteria
This was a multicentre, prospective, randomised, double-
blind, placebo-controlled clinical study with parallel group
design. Patients with cystic fibrosis, chronic P. aeruginosa
(PA) infection and an acute respiratory exacerbation were
eligible for participation if they had successfully completed
an IV course of antipseudomonal combination treatment
(the majority received a b-lactam antibiotic and an amino-
glycoside) within 1 week before the projected start of study
medication. Intravenous treatment was considered success-
ful if a clinically relevant improvement of respiratory symp-
toms and/or lung function was achieved after antibiotic
treatment. Chronic P. aeruginosa infection was defined as
a PA positive sputum/throat swab before the acute epi-
sode/exacerbation leading to IV antibiotic treatment, and
2 or more courses of systemic antipseudomonal antibiotics
within the 12months preceding the acute episode (the latter
requirement was removed after an amendment to the study
protocol). Long-term inhaled antibiotics were allowed if
they had been installed at least 4 weeks before the study
started and the dosage had not been changed during the
study. Further inclusion criteria were: age 8 years or older,
body weight 20 kg, and forced expiratory volume in 1 s,
FEV1, in a range of 30e80% of the predicted normal value
at the end of the initial course of IV antibiotics. Cystic fibro-
sis had been diagnosed with positive sweat tests or cystic fi-
brosis transmembrane regulator (CFTR) mutation analyses.
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excluded: (a) treatment with any macrolide, azalide or
ketolide antibiotic within 10 weeks prior to the baseline
visit, (b) concurrent treatment with any systemic antibiotic
other than the study medication, (c) regular elective
systemic antipseudomonal treatments several times
a year in the absence of pulmonary exacerbations, (d)
concomitant treatment with systemic corticosteroids, cy-
closporine A, ergot alkaloids, or triazolam, (e) acute
pneumothorax, (f) bronchoalveolar lavage during the hos-
pitalisation preceding visit 1, and (g) colonization with
Burkholderia cepacia complex.
Further exclusion criteria were clinically relevant renal,
cardiac, or hepatic (ALT/AST >3 times of the upper normal
limit, portal hypertension) dysfunction, chronic gastroin-
testinal disease not related to CF, pregnancy, lactation,
inadequate contraception in sexually active females, and
intolerance or allergy to study medication, macrolides,
azalides or ketolides.
Patients were recruited from 11 certified CF centres in
Germany (nZ 10) and Switzerland (nZ 1), which provide
both inpatient and outpatient facilities. Ethics committee
approval was secured for the protocol from the respective
ethics committees.
The duration of the study for the individual patient was 8
weeks. There were 2 study visits: Visit 1 (baseline) was
performed at the end of the initial intravenous antibiotic
treatment, and Visit 2 (day 56, end of study) took place
after 8 weeks of study medication.
Study medication
Azithromycin (Zithromax) was provided as 250 mg tablets,
and placebo tablets were made to look and taste identical
to the antibiotic. Depending on body weight, patients re-
ceived the following dosages of azithromycin (or matching
placebos): 20e29 kg: 500 mg (2 tablets), 30e39 kg: 750 mg
(3 tablets), 40e49 kg: 1000 mg (4 tablets), and 50 kg:
1250 mg (5 tablets).
Study medication was taken once per week for 8 weeks.
The first dose was administered within 1 week after the end
of IV treatment. The day of the week when study medica-
tion was to be taken was chosen such that it was 3
weekdays before Visit 2 (end of study). Patients were
advised to take the tablets after a meal. If the patient
forgot to take the study medication, he or she could take it
within 3 days of the scheduled administration time point.
Efficacy endpoints
Primary and secondary endpoints
The primary endpoint was the absolute change in FEV1 (%
predicted)16 at the end-of-study treatment, compared
with the baseline value before study medication. Secondary
endpoints were changes compared to baseline of clinical
signs and symptoms, spirometry, oxygen saturation, bacte-
riologic assessments, quality of life, inflammatory parame-
ters (C-reactive protein, total IgG, and interleukin-8 (IL-8)
in serum) and sputum parameters (alginate production of
P. aeruginosa, sputum viscoelasticity, chloride secretion,
DNA concentrations). Sputum and serum azithromycinconcentrations were measured, and the safety and tolera-
bility of azithromycin were documented. Compliance was
estimated by calculating the mean number of tablets taken
per week minus the number of prescribed tablets per week.
Clinical symptoms and spirometry
Cough, dyspnoea, chest pain, and rales/rhonchi were classi-
fied as being either absent, mild, moderate or severe, and
haemoptysis was categorized as being either absent or
present. Sputum volume in the morning was categorized as
follows: no sputum, teaspoon, tablespoon, 1/4 cup, or 1/2
cup. Spirometrywas performed according toQuanjer et al.,16
and the following parameterswere reported: inspiratory vital
capacity (IVC), forced vital capacity (FVC), forced expiratory
volume at 1 s (FEV1), and forced expiratory flow between 25
and 75% of expiratory vital capacity (FEF75e25%). Oxygen satu-
ration was determined either by pulse oximetry or by blood
gas analysis from arteriolised blood from the ear.
Laboratory methods
Haematology including differential count, serum concen-
trations of immunoglobulin G (IgG) and C-reactive protein
(CRP), and bacteriological assessments were determined in
the local laboratory of each centre using standard labora-
tory methods.
Alginate production of P. aeruginosa was determined at
Prof. Gerd Do¨ring’s laboratory (Hygiene Institute, Univer-
sity of Tu¨bingen, Germany) from sputum specimens of at
least 3 ml using the carbazole method.17,18 Chlamydia
pneumoniae and Mycoplasma pneumoniae in sputum and
serum were searched for using both serology (IgG, IgA,
IgM) and a polymerase chain reaction (PCR). Specimens
were transported to the laboratory of Prof. Marianne
Abele-Horn (Institute for Microbiology, University of Wu¨rz-
burg, Germany). Azithromycin concentrations in sputum
and serum were measured with HPLC and mass spectrome-
try at the Department of Pharmacology and Pharmacoepi-
demiology, University of Heidelberg, Germany (Prof.
Walter E. Haefeli). Samples were obtained on day 56, 3
days after the last dose of study medication had been
taken. Interleukin-8 (IL-8) and lipopolysaccharide binding
protein (LBP) were analyzed using a two-sided chemilumi-
nescent test (Immulite DPC, Bad Nauheim, Germany). In
addition, serum concentrations of tumour necrosis factor
receptor types 1 and 2 (TNF-R1/R2), and soluble endotoxin
receptor (sCD14) were determined by commercial ELISAs
according to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN, USA). Sensitivity of the tests were 2.0 pg/
ml for IL-8, 0.2 mg/ml for LBP, 0.77 pg/ml for TNF-R1,
0.6 pg/ml for TNF-R2 and 125 pg/ml for sCD14. All cytokine
studies were performed in the laboratory of Prof. Zielen
(University Children’s Hospital, Frankfurt, Germany).
Quality of life (QoL)
Patients reported their QoL using the validated German
version of the cystic fibrosis questionnaire (CFQ).19 If the
children were younger than 13 years, the parents re-
sponded to the CFQ-E version of the questionnaire. Older
patients used the CFQ-14þ version, and adults used the
CFQ-18þ form. Each scale has an optimum of 100 and
a (theoretical) minimum of 25 points, and higher values
indicate an improvement of quality of life.
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Considering the results reported by Wolter et al.,11 we be-
lieved that the differences in FEV1 between AZM and pla-
cebo groups after 8 weeks of treatment would be 3.8%
predicted with a standard deviation of 7.3%. Based on
0.80 power to detect a significant difference (pZ 0.05,
two-sided), 65 evaluable patients were required for each
study group. To compensate for nonevaluable patients,
we planned to enrol 75 patients per group.
Allocation to treatment
Azithromycin or placebo tablets were allocated to patients
according to a computer-generated randomization list
which had been prepared consistent with the sponsor’s
standard operating procedures. The study physician allo-
cated the next available number on entry into the trial. All
study personnel and participants were blinded to treatment
assignment for the duration of the study.
Definition of analysis sets
The safety population involved all patients who had re-
ceived at least one dose of the study medication. The
intent to treat (ITT) population consisted of all subjects of
the safety population for whom at least one on-treatment
efficacy measure was available. The per protocol popu-
lation (PP) analysis set consisted of all patients of the ITT
population who did not show any severe protocol
deviations.
Statistical analysis
All data analysis was carried out according to a pre-
established analysis plan. Statistical testing was performed
at a significance level of aZ 5%. Demographic variables,
other baseline characteristics and all efficacy variables
were analyzed in the ITT analysis set. The primary efficacy
criterion, FEV1, was also analyzed in the PP analysis set.
The primary endpoint, absolute change in the FEV1 (%),
was tested using an ANCOVA model, and the following cova-
riates were incorporated in the model: Baseline FEV1 (as
a percentage of the predicted normal value), age, duration
of P. aeruginosa infection, number of courses of systemic
antipseudomonal antibiotic treatments within the last 12
months, treatment with inhaled antibiotics, and treatment
with dornase alfa.
An exploratory analysis was performed for the secondary
efficacy variables using a similar ANCOVA model. Categor-
ical variables were analyzed with appropriate linear
models.
All safety variables were analyzed in the safety analysis
set in accordance with Pfizer’s worldwide safety standards
(WSS), release 3.0. Adverse events were coded according to
MedDRA, version 7.1.
Results
Study participants
Of the 40 patients screened in 11 study centres, 38 patients
were randomised (21 to AZM and 17 to placebo) and
received at least one dose of study medication (Fig. 1).
Two patients were not eligible because of (a) hearing lossand (b) a baseline FEV1 value of only 22% of predicted.
Nine participants (23.7%) prematurely discontinued the
study, 6 of these (2 in the AZM and 4 in the placebo group)
due to an adverse event. The 17 and 12 patients who com-
pleted the study in the AZM and placebo groups, respec-
tively, were recruited between November 2001 and June
2004.
Nine protocol deviations (nZ 4 in the AZM and nZ 5 in
the placebo group) were judged as major events (e.g. con-
comitant systemic antibiotic treatment (nZ 4), or visit
‘‘day 56’’ performed between days 4 and 25 after first
dose of study drug (nZ 5)), so that the respective patients
were not included in the per protocol group.
Baseline demographic and clinical characteristics
The mean (SD) age of the whole patient cohort was 24.8
(10.0) years, and 16 of 21 participants in the AZM group and
13 of 17 placebo patients were adults (Table 1). The average
duration of PA infection was 10.4 (6.6) years. In the year pre-
ceding the study, the patients had received 2.4 (1.1) courses
of systemic antibiotic treatments on the average. Immedi-
ately before the start of the study, patients had experienced
a respiratory exacerbation which was treated with systemic
combination antipseudomonal antibiotics, predominantly
tobramycin (nZ 34), ceftazidime (nZ 18) and meropenem
(nZ 12). These antibiotics were administered during a hos-
pital stay in 22 patients and at home in the remaining 16 sub-
jects. Thirty participants used long-term inhaled antibiotics
on a routine basis (colistine: nZ 17, tobramycin: nZ 13,
additional polymyxin B: nZ 1).
In accordance with the inclusion criteria, most patients
had moderate to severe lung disease with both central and
peripheral airways obstruction (Table 1). Ten patients com-
plained of moderate or severe cough and produced 1/4 cup
or more of sputum per day, despite of the fact that they
had received antipseudomonal antibiotics immediately be-
fore the start of the trial. Only 6 patients reported no cough
and 2 subjects no sputum. P. aeruginosa was identified in
respiratory secretions of 17 AZM and 10 placebo patients,
and Staphylococcusaureus grew in 5 and 3 specimens from
the respective groups.
Regarding quality of life, the worst scores were found in
the subscales energy, daily living, and respiratory symptoms.
No statistically significant differences between groups
were found with respect to baseline demographic and
clinical characteristics.
The first dose of study medication was administered at
a mean (SD) of 4.8 (2.6) days after the end of the preceding
intravenous antipseudomonal treatment.
Efficacy
The primary analysis of efficacy was intent-to-treat and
involved all randomised patients who received at least one
dose of study medication.
FEV1 and spirometry
We expected lung function to decline after cessation of IV
antibiotics. Accordingly, mean FEV1 decreased by 3.7% (SD
n = 38
Patients randomized
n = 38
Patients receiving
study medication
n = 21
Azithromycin
n = 17
Placebo
n = 17
Completed
study
n = 4
Withdrawn
n = 12
Completed
study
n = 5
Withdrawn
Violation of inclusion / exclusion
criteria (n = 1)
Adverse event (n = 2)
Protocol violation (n = 1)
Violation of inclusion / exclusion
criteria (n = 1)
Adverse event (n = 4)
n = 40
Patients screened
n = 2
Screening failures
Hearing loss (n = 1)
FEV1 value <30 % (n = 1)
Figure 1 Patient flow.
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predicted in the placebo groups, respectively. The mean
absolute change of FEV1 (%) adjusted to baseline FEV1 (%)
did not differ significantly between treatment groups
(pZ 0.708). Analysis of the per protocol groups revealed
similar results: FEV1 decreased by 4.4% (SD 14.1%) in the
AZM and by 5.2% (SD 11.2%) in the placebo group
(pZ 0.826). The change of FEV1 (%) from baseline was an-
alyzed with an ANCOVA model including, besides treat-
ment, the following covariates: baseline FEV1 (%), age
(years), duration of colonization with P. aeruginosa (years),
number of courses of systemic antipseudomonal antibiotic
treatments within the last 12 months, treatment with in-
haled antibiotics (yes, no) and treatment with dornase
alfa (yes, no). None of these factors had a statistically sig-
nificant (aZ 0.05) influence on FEV1. Treatment responses
were comparable in subgroups of patients treated with
inhaled antibiotics (nZ 21) and/or dornase alfa (nZ 17).Other respiratory function parameters (IVC, FVC,
MEF75e25, and oxygen saturation) also declined during the
study (Table 2), and AZM had no statistically superior
effects compared to placebo.Inflammatory parameters
Results for inflammatory parameters are summarised in
Table 3. Immediately after intravenous antibiotics (and be-
fore study start), CRP was still elevated (>3 mg/l) in 8 of
21 AZM and in 4 of 16 placebo patients, so that mean
CRP serum concentrations were increased at baseline
(Table 3). After AZM and placebo treatment, CRP was ab-
normal in 9 and 11 patients, respectively, and the compar-
ison of changes within groups (AZM: 0.9 mg/l (SD 6.6 mg/l),
placebo: 21.6 mg/l (SD 60.4 mg/l)) showed a significant
difference (pZ 0.019, ANCOVA) at day 56 (Fig. 2). ANCOVA
Table 1 Baseline characteristics
Azithromycin (NZ 21) Placebo (NZ 17)
Mean age (SD) (years) 23.7 (7.6) 26.3 (12.5)
Adults (18 years) (n %) 16 (76.2) 13 (76.4)
Male sex, (n %) 14 (67) 7 (41)
Mean weight (SD) (kg) 55.4 (8.9) 54.3 (16.7)
Mean height (SD) (cm) 167.3 (10.8) 163.3 (15.5)
P. aeruginosa identified (n %) 17 (81.0) 10 (62.5)
Mean duration of P. aeruginosa infection (years) 11.2 9.4
Courses of systemic antipseudomonal therapy within the last 12 months (n) 2.5 2.2
Patients previously treated with inhaled antibiotics (n %) 17 (81.0) 13 (76.5)
Mean FEV1 (SD) (% predicted value) 63.0 (15.5) 60.1 (12.3)
Mean IVC (SD) (% predicted value) 78.2 (16.4) 75.7 (15.0)
Mean FVC (SD) (% predicted value) 79.0 (15.4) 76.3 (16.2)
Mean FEF75e25% (SD) (% predicted value) 29.6 (12.1) 27.3 (13.2)
Mean oxygen saturation (%) 95.7 (1.8) 95.7 (1.8)
Diary: mean symptom scoresa for
Cough 1.05 1.18
Dyspnoea 0.24 0.35
Chest pain 0.10 0.00
Sputum 1.52 2.06
a 0Z Absent, 1ZMild, 2ZModerate, 3Z Severe.
1648 G. Steinkamp et al.revealed a significant influence of the number of previous
antipseudomonal treatment courses on change of CRP.
Interleukin-8 serum concentrations decreased after 8
weeks of AZM treatment (3.1 pg/ml) and increased after
placebo (þ2.9 pg/ml) (Fig. 2), with significant differences
(pZ 0.001) between groups. Lipopolysaccharide binding
protein (LBP) in serum also showed significantly better re-
sults (pZ 0.015) after AZM (increase of only 0.9 mg/ml,
Fig. 2) than after placebo (7.0 mg/ml). Patients treated
with azithromycin did not differ from placebo patients re-
garding the development of other inflammatory parame-
ters, such as IgG, tumour necrosis factor receptor types 1
and 2 (TNF-R1/R2) or soluble endotoxin receptor (sCD14).
Bacteriology and serology
At start of study medication (immediately after intravenous
antibiotics), PA was cultured in respiratory secretions ofTable 2 Spirometry: mean changes after 8 weeks of
treatment
Azithromycin
(NZ 21)
Placebo
(NZ 17)
Mean FEV1 (SD)
(% predicted value)
3.7 (13.3) 5.0 (10.1)
Mean IVC (SD)
(% predicted value)
4.1 (15.5) 5.1 (13.3)
Mean FVC (SD)
(% predicted value)
3.1 (15.5) 7.1 (10.9)
Mean FEF75e25% (SD)
(% predicted value)
1.1 (7.5) 3.1 (20.1)
Mean oxygen
saturation (%)
0.4 (1.5) 0.6 (2.2)81% of patients in the AZM group and of 63% of placebo
patients. Only 75% of patients were PA positive after 8
weeks of azithromycin treatment, whereas all placebo
patients grew PA in their sputa at day 56. S. aureus was
found in 19% of patients at baseline, regardless of treat-
ment group. At day 56, 17% of AZM and 50% of placebo sub-
jects were positive for S. aureus. No differences were
detected regarding other pathogens.
At start of study medication, 2 of 13 AZM and 1 of 10
placebo patients had antibodies against M. pneumonia, and
serologic evidence of C. pneumoniae infection was found in
5 of 13 AZM and 3 of 10 placebo subjects. No relevant
changes were observed after 8 weeks of treatment.
Alginate in sputum
At baseline, alginate produced by mucoid P. aeruginosa
strains was detected in sputum in considerable amounts,
with no difference between groups. After 8 weeks of AZM
treatment, the mean increase in alginate concentrations
was significantly lower than in placebo patients (85
compared to 353 mg, pZ 0.048) (Table 3, Fig. 3). ANCOVA
revealed that the absolute changes in alginate concentra-
tions between baseline and final values were significantly
larger with (a) a longer duration of PA colonization and
(b) more courses with systemic antipseudomonal antibiotics
within the last 12 months, whereas changes in alginate
were smaller in patients with lower baseline alginate
concentrations.
Signs and symptoms
At day 56, mean cough and sputum scores were 1.3 and 1.9
in patients with AZM and 1.5 and 2.6 in placebo patients,
respectively. A larger proportion of placebo (10 of 17) than
Table 3 Inflammatory parameters in serum and sputum before and after treatment (Mean, SD)
Parameter Azithromycin Placebo
n Baseline Day 56 n Baseline Day 56
Serum
CRP (mg/l) 21 7.3 (11.3) 8.2 (9.9) 16 6.2 (10.2) 27.8 (58.7)
IgG (mg/dl) 21 1686 (435.4) 1640 (449.6) 17 1675 (415.6) 1607 (430.5)
IL-8 (pg/ml) 18 14.1 (14.5) 11.0 (3.8) 15 12.0 (9.8) 14.9 (12.8)
LBP (mg/ml) 20 8.0 (3.1) 8.9 (2.8) 16 7.5 (3.1) 14.5 (10.6)
TNF-R1 (pg/ml) 20 1027 (224.3) 1027 (211.5) 16 1035 (180.7) 1265 (411.7)
TNF-R2 (pg/ml) 20 2137 (497.7) 1962 (369.0) 15 2264 (743.9) 2463 (734.8)
sCD14 (ng/ml) 20 1118 (264.8) 1222 (276.2) 14 1074 (186.5) 1320 (223.8)
Sputum
Alginate (mg/ml) 11 253.2 (307.4) 338.2 (234.0) 9 361.1 (444.4) 714.4 (515.0)
Azithromycin in cystic fibrosis with chronic P. aeruginosa infection 1649of AZM (5 of 21) patients produced more than a tablespoon
of sputum per day. No relevant differences between groups
were present with respect to other signs and symptoms.
Quality of life
The results of the CFQ-14e18þ questionnaires revealed
relevant differences between treatment groups. Eight
weeks after start of treatment, patients on AZM rated their
quality of life significantly better than placebo patients
with respect to body weight (pZ 0.021), respiratory symp-
toms (pZ 0.037), and eating disorder (pZ 0.046). Patients
reported considerable improvements in their daily living,
with numerically larger benefits in patients treated with
azithromycin (Fig. 4). Ten of 14 CFQ subscales showed
more favourable mean changes between baseline and visit
day 56 after AZM compared to placebo.
The CFQ-E version of the questionnaire was used for
nZ 3 AZM children and for nZ 4 placebo patients. The re-
sponses of parents showed no clear trends in favour of one
or the other study drug.
AZM serum and sputum concentrations
Azithromycin-treated patients received a body weight
adjusted weekly dosage of 21.2 mg/kg body weight on theFigure 2 Inflammatoryaverage (SD 2.0 mg/kg). On day 56, azithromycin concen-
trations were detected in serum in all but 3 AZM patients,
with a mean on-treatment concentration of 57.7 ng/ml
(SD 33.3 ng/ml). Patients had taken the last dose of AZM 3
days before the end-of-study visit. In 2 patients blood sam-
ples were drawn later than requested (5 and 24 days after
the last dose), and in 1 patient AZM was not detected in se-
rum on the appropriate day, so that this patient was ex-
cluded from the per protocol analysis. Azithromycin was
found in sputum in 11 of 11 treated patients, with a mean
concentration of 14.4 mg/g (SD 10.1 mg/g) after 8 weeks of
once-weekly azithromycin. No azithromycin was measured
in serum or sputum in any placebo patient.
Tolerability and safety
In general, study medication was well tolerated. Thirty
adverse events (AEs) occurred in 13 patients (62%) of the
azithromycin group, and 40 adverse events occurred in 10
patients (59%) of the placebo group. Of the treatment-
related adverse events, 10 occurred in 4 patients (19.0%)
on AZM, and 11 developed in 3 patients (17.6%) on
placebo. General disorders and administration site condi-
tions (asthenia, decreased exercise tolerance, influenza
like illness, pyrexia) as well as gastrointestinal disorders
(upper abdominal pain, dyspepsia, nausea) were moreparameters in serum.
Figure 3 Alginate in sputum.
1650 G. Steinkamp et al.frequent in those receiving placebo (nZ 3/3) than in pa-
tients on AZM (nZ 2/1). Respiratory, thoracic and medi-
astinal disorders (cough) (nZ 2), infections and
infestations (bronchopneumonia, rhinitis) (nZ 1) and a de-
crease in pulmonary function test (nZ 1) were observed
with similar frequency in both groups. Nervous system dis-
orders (dizziness, headache) were more frequent in those
receiving AZM (2 vs. 1), the same was true for skin and
subcutaneous tissue disorders (urticaria) (1 vs. 0). No se-
rious or severe treatment-related AEs occurred in this
study. One patient in each treatment group prematurely
discontinued the study due to treatment-related AEs.
There was no clinically significant deterioration of audi-
tory performance in any patient and no newly diagnosed
hearing loss at visit day 56. Moreover, no systematic
changes of laboratory parameters and vital signs wereFigure 4 Mean changdetectable in any of the two treatment groups between
baseline and visit day 56.Discussion
The present double-blind trial evaluated the once-weekly
dosing of azithromycin compared to placebo in patients
with cystic fibrosis. All patients had completed a course of
intravenous antipseudomonal antibiotics directly before
the start of the study medication. Thus, many participants
were in their individual optimum clinical condition when
the trial commenced. Not surprisingly, we observed a de-
crease in pulmonary function parameters during the fol-
lowing 8 weeks, which was of comparable extent in the
azithromycin and in the placebo groups. Other study
endpoints showed that patients experienced a significant
benefit from azithromycin. Inflammatory parameters such
as CRP, IL-8 and LBP developed more favourably in patients
on AZM. Three of the 14 subscales of the CFQ-14þ/18þ
questionnaire (problems with body weight, eating disorder,
and respiratory symptoms) showed significantly better
quality of life in participants treated with azithromycin.
To our knowledge, this is one of the first trials in cystic
fibrosis patients with once-weekly administration of azi-
thromycin. In the middle of the dosage interval, we
reached mean concentrations of 57.7 ng/ml in serum and
14.4 mg/g in sputum. When healthy volunteers received
a single dose of 1500 mg AZM, mean serum concentrations
between 3 and 10 days after administration were in the
range of approximately 60 ng/ml.20 Adults with CF who
were on long-term treatment with daily doses of 500 mg
AZM, i.e. a threefold weekly dose compared to the present
study, showed considerably higher peak serum concentra-
tions (mean Cmax: 670 ng/ml) than our study participants.
15
Sputum levels ranged from 4 to 27 mg/l (w27 mg/g) at 10
days after the last dose and were comparable to thees in quality of life.
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weekly dosing we achieved serum and sputum concentra-
tions that did not differ markedly from those reported in
the literature as being therapeutically efficient.21
Once-weekly azithromycin dosing was well tolerated by
the patients. No relevant differences in frequency and
intensity of adverse events were noted between the AZM
and the placebo groups. Saiman et al. reported more
frequent gastrointestinal symptoms (nausea and diarrhoea)
and wheezing after 500 mg AZM 3 days a week.9 In the pres-
ent study, treatment-related gastrointestinal disorders oc-
curred in 11.8% of placebo and 4.8% of AZM patients, and
wheezing was not reported as an adverse event in any pa-
tient. The application of the drug on a specific day of the
week might be easier to remember than the weekdays for
three doses per week, and the dose applied is lower than
in daily dosing of 500 mg. Thus, this treatment regimen
could improve patient compliance and save costs for the
health system. A recent trial compared daily vs. weekly azi-
thromycin in cystic fibrosis in 208 CF patients: In patients
aged <18 years the daily group had significantly better im-
provements in z-scores for height and weight after 6
months.22 Equivalence was demonstrated between the 2
groups with respect to improvements in lung function
(FEV1 and FVC), CRP, days spent in hospital, admission
rate and nutrition (body mass index, z-scores).
Another important feature of our study was that only
patients who had successfully completed a course of
intravenous antipseudomonal antibiotics were enrolled, re-
spectively, were at their individual optimum when entering
the trial. This is in sharp contrast to the larger multicentre
trials on azithromycin in CF, which required an interval of
some weeks since the last IV treatment had been adminis-
tered. Much of the benefit obtained by intravenous antibi-
otics is lost already 4 weeks after discharge from hospital
and so we expected pulmonary function and clinical symp-
toms to decline during the study, at least in the placebo
group. A decrease in FEV1 of 4e5% of the predicted normal
value occurred, and contrary to our hypothesis, AZM of-
fered no benefit over placebo in this respect. The interpre-
tation must take into account that fewer patients were
admitted than initially planned. Difficulties to recruit the
projected number of patients were mainly caused by the
stimulating results of preceding studies on azithromycin in
cystic fibrosis.
Inflammation tended to spread out within 8 weeks after
finishing systemic antipseudomonal antibiotics. At start of
the study CRP levels in patients were slightly elevated
compared to normal’s, and increased significantly in the
placebo group during the observation period but not in
those receiving azithromycin. The CRP values at start were
comparable to those of Downey et al.23 Wolter and co-
workers reported median CRP values to decline steadily
over time during AZM therapy,11 supporting our finding
that azithromycin had a favourable effect on the increase
in serum CRP. Interestingly, it was recently shown that se-
verity of lung disease in long surviving adult CF patients is
correlated with CRP and IgG levels.24
A novel finding is the decrease in serum IL-8 observed
during AZM therapy, whereas placebo patients experienced
an increase after termination of IV antipseudomonal treat-
ment. The underlying molecular mechanism was recentlystudied in CF airway epithelial cell lines.25 It was shown
that AZM downregulates NF-kB and AP-1 DNA binding indi-
cating inhibition of transcription of pro-inflammatory genes
as a possible mechanism.
We also found that lipoprotein binding protein (LBP)
increased to a significantly larger extent in the placebo
than in the azithromycin group. LBP plays an essential role
in the immune response to gram-negative bacterial in-
fection. Lipopolysaccharide (LPS) recognition requires LPS-
binding protein and CD14. Both LBP and CD14 control ligand
presentation to the receptor complex Toll-like receptor
(TLR4) and influence the amplitude of LPS responses and
LPS-induced type I interferon production. In previous
studies, LBP and IL-8 correlated negatively with clinical
status and lung function in homozygous F508del cystic
fibrosis patients.26,27 In this regard a significantly lower
IL-8 and LBP should reflect a clinical benefit for the patient.
It is tempting to speculate that reduced levels of CRP,
LBP, and IL-8 indicate a lower bacterial load in the airways
of patients treated with AZM. This is in keeping with lower
concentrations of sputum alginate which could imply less
microcolony formation of P. aeruginosa and less bacterial
evasion of host defence.2 Alginate is a major constituent
of P. aeruginosa biofilms. Biofilm formation by P. aeruginosa
was inhibited in vitro by AZM concentrations well below the
MIC.28 Quorum sensing (QS) controls virulence factor pro-
duction and biofilm formation.17 A recently published study
investigated the impact of AZM on the global transcriptional
pattern and the protein expression profile of P. aeruginosa
cultures vs. those in untreated controls.6 By downregula-
tion of quorum-sensing-dependent genes, AZM exhibited
extensive quorum-sensing antagonistic activities. In the
present study, we showed for the first time that mean spu-
tum alginate concentration after treatment was signifi-
cantly lower in participants receiving AZM compared to
the placebo group. Moreover recently Hansen and co-
workers29 also reported after 1-year treatment with low
dose AZM (250 mg) daily in adult CF patients a highly signif-
icant (pZ 0.003) reduction in the number of sputum sam-
ples positive for mucoid strains from 90% in the year
before treatment to 81% in the year of AZM treatment. An-
other bacterial anti-virulent effect of AZM has been shown
lately in a 6-month clinical trial in American CF patients.
Nguyen et al.30 were able to provide evidence that the
change of phospholipase C (PLC) was significantly negative
correlated with the change in FEV1 (pZ 0.05) and occur-
rence and time to pulmonary exacerbation (both pZ 0.02).
In addition we found that the frequency of neither P.
aeruginosa nor S. aureus increased in respiratory secretions
from participants treated with AZM, in contrast to placebo
patients, who had a greater percentage of positive bacteri-
ological results after 8 weeks.
Interestingly, the patients’ quality of life was signifi-
cantly better after AZM. Using validated German versions of
the CFQ questionnaire for three different age groups,19 we
found significantly better results for the subscales problems
with body weight, eating disorder and respiratory symp-
toms in adolescents and adults after 8 weeks of azithro-
mycin treatment compared to placebo. In particular,
deteriorations of more than 5 points (mean) occurred in 4
of the 14 scales after placebo (and in none after AZM),
whereas azithromycin treatment caused improvements by
1652 G. Steinkamp et al.5 or more points in 5 subscales (placebo group: 1 subscale
only). In the US trial, quality of life improved regarding
the scale ‘‘physical factor’’ of the CF quality of life ques-
tionnaire,31 whereas the other three components remained
unchanged.9
The present study had some limitations. The results
from sputum measurements include a subgroup of patients
only, since others were unable to expectorate sufficient
amounts of sputum after successful intravenous antibiotic
treatment.
In conclusion, once-weekly azithromycin ameliorated
inflammatory airway response indicating a reduced bacte-
rial load in treated patients. Furthermore, AZM improved
quality of life of patients chronically infected with P. aeru-
ginosa who had successfully completed a course of intrave-
nous antibiotics for an exacerbation. Treatment was well
tolerated and did not cause an increase of treatment-
related adverse events compared to placebo. These result
suggest that one dose of azithromycin per week may repre-
sent an alternative treatment regimen for patients with
cystic fibrosis.
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